Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

15.95
+0.75004.93%
Post-market: 15.950.00000.00%19:46 EST
Volume:2.83M
Turnover:43.94M
Market Cap:2.32B
PE:-6.21
High:16.50
Open:15.10
Low:14.01
Close:15.20
Loading ...

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Ardent Health Partners, Inc. (ARDT) and Doximity (DOCS)

TIPRANKS
·
30 mins ago

Stock Track | Denali Therapeutics Plummets 5.16% as Price Target Cut on Lowered Probability of Success

Stock Track
·
Yesterday

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer

TipRanks
·
Yesterday

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?

Insider Monkey
·
Yesterday

Denali Therapeutics : Oppenheimer Cuts Target Price to $42 From $50

THOMSON REUTERS
·
03 Mar

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus

Zacks
·
01 Mar

Denali Therapeutics (DNLI) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
28 Feb

Denali: Entered Equity Distribution Agreement, Pursuant to Which Co May Offer, Sell Shares of Co Common Stock of up to $400 Mln From Time to Time

THOMSON REUTERS
·
28 Feb

BRIEF-Denali Therapeutics Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
28 Feb

Denali Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Denali Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
28 Feb

BRIEF-Denali Therapeutics Q4 Operating Income USD -129.846 Million

Reuters
·
28 Feb

Denali Therapeutics Inc - Expects 10%-15% Increase in Cash Operating Expenses for 2025

THOMSON REUTERS
·
28 Feb

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
10 Feb

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Zacks
·
07 Feb

Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II

TIPRANKS
·
07 Feb